MedTrace Logo

A Study of AZD4901 in Females With Polycystic Ovary Syndrome

NCT01872078 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 67

Last updated 2015-10-12

Study results available
· View outcomes & findings →

Summary

To assess the effects of AZD4901 when given in multiple doses to females with Polycystic Ovary Syndrome

Conditions

  • Polycystic Ovary Syndrome (PCOS), Female Endocrine Disorder

Interventions

DRUG

AZD4901 (oral)

Patients randomized to 1 of 4 treatment groups: AZD4901 20 mg once a day, AZD4901 20 mg twice a day, AZD4901 40 mg twice a day or placebo

DRUG

Placebo to match AZD4901

Patients randomized to 1 of 4 treatment groups: AZD4901 20 mg once a day, AZD4901 20 mg twice a day, AZD4901 40 mg twice a day or placebo

Sponsors & Collaborators

Principal Investigators

  • Jyothis George, MD · University of Oxford

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2014-07-31
Completion
2014-07-31

Countries

  • United States
  • Germany
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01872078 on ClinicalTrials.gov